Related Experiment Video
Updated: May 8, 2026
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Emerging Therapeutic Targets and Signaling Networks in Ischemia-Reperfusion Injury
Shreeya Bhujbal1, Lokesh Kumar Bhatt1
1Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Abstract:
Ischemia-reperfusion injury remains a major challenge in modern regenerative medicine due to its complex mechanisms, lack of effective therapies, and persistent constrains to translating new interventions from bench to bedside. Currently, there are no FDA-approved drugs that directly target ischemia-reperfusion injury, highlighting a substantial therapeutic gap. While restoring blood flow is vital for salvaging ischemic tissue, the reperfusion process paradoxically triggers additional cellular damage. The clinical significance and complexity of ischemia-reperfusion injury underscore an urgent need for mechanistically targeted therapeutic approaches. Recent research has identified pivotal molecular targets-PHLDA1, SIRT6, PKM2, and ubiquitin-specific proteases (USPs)-that play key roles in modulating cellular responses such as oxidative stress, inflammation, metabolism, apoptosis, autophagy, ferroptosis, and blood-brain barrier dysfunction during ischemia reperfusion injury. Advances in understanding these mechanisms offer promising strategies for developing novel interventions to mitigate tissue damage and improve patient outcomes. This review critically examines these molecular targets, detailing recent advances and outlining future directions in ischemia reperfusion injury research.
Insights
Ischemia-reperfusion injury poses a significant challenge in regenerative medicine. Targeting key molecular pathways like PHLDA1 and SIRT6 offers promising therapeutic strategies to mitigate tissue damage and improve patient outcomes.
Area of Science:
- Regenerative Medicine
- Molecular Biology
- Pathophysiology
Background:
- Ischemia-reperfusion injury (IRI) is a major obstacle in regenerative medicine, lacking effective therapies.
- Restoring blood flow can paradoxically worsen tissue damage, creating a therapeutic gap.
- No FDA-approved drugs currently exist to directly target IRI.
Purpose of the Study:
- To review recent advances in understanding the molecular mechanisms of IRI.
- To examine novel therapeutic targets for mitigating IRI.
- To outline future research directions in IRI.
Main Methods:
- Literature review of recent research on IRI molecular targets.
- Analysis of key proteins (PHLDA1, SIRT6, PKM2, USPs) involved in IRI.
- Examination of cellular responses modulated by these targets.
Main Results:
- Identified PHLDA1, SIRT6, PKM2, and ubiquitin-specific proteases (USPs) as pivotal molecular targets in IRI.
- These targets modulate critical cellular processes including oxidative stress, inflammation, metabolism, and cell death.
- Understanding these mechanisms provides a basis for novel therapeutic interventions.
Conclusions:
- Targeting specific molecular pathways offers a promising strategy for developing effective IRI therapies.
- Further research into these targets can lead to improved patient outcomes in regenerative medicine.
- Addressing the complexity of IRI requires mechanistically targeted approaches.
